Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the Kennedy Institute of Rheumatology have used 3D and live-imaging to show how resident memory B cells boost antibodies to fight influenza.

Confocal microscopy of a lung section, 4 days after being rechallenged with an influenza virus.
Confocal microscopy of a lung section, 4 days after being rechallenged with an influenza virus. Resident memory B cells (red) and newly generated plasma cells (yellow) can be seen in very close proximity to infected cells (light blue).

In a paper published in Immunity, the research has for the first time defined the mechanisms that enable resident memory B (BRM) cells to rapidly deliver antibodies at sites infected with the influenza virus.

Tal Arnon, Associate Professor at the Kennedy Institute said: "Resident memory B cells develop in the lungs of influenza-infected hosts. We uncovered a new network of innate-adaptive cell interactions that coordinates the recruitment of BRM cells to infected sites, subsequently leading to the accumulation of plasma cells directly within these regions."

The study used 3D and two-photon microscopy to visualise the BRM cells within the lungs of influenza-virus immune and reinfected subjects. The tissues were rechallenged with the virus and the BRM cells tracked in situ. During the memory phase, prior to reinfection, the cells were sparsely scattered across the alveoli displaying limited migration capabilities. However, within 24hrs after secondary infection, the cells doubled their mean migration speeds, travelled long distances to accumulate at the infected site, and subsequently differentiated into plasma cells.

Read the full story on the Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences website

Similar stories

Oxford spinout trials revolutionary bioelectronic implant to treat incontinence

The first participants in a clinical trial of a bioelectrical therapy to treat incontinence have received their “smart” bioelectronic implants.

COVID-19 is a leading cause of death in children and young people in the US

A new study led by researchers at the University of Oxford’s Department of Computer Science has found that, between 2021 and 2022, COVID-19 was a leading cause of death in children and young people in the United States, ranking eighth overall. The results demonstrate that pharmaceutical and public health interventions should continue to be applied to limit the spread of the coronavirus and protect again severe disease in this age group.

Three or more concussions linked with worse brain function in later life

Experiencing three or more concussions is linked with worsened brain function in later life, according to new research.

New blood test could save lives of heart attack victims

Researchers in the Department of Physiology, Anatomy and Genetics (DPAG) have developed a blood test that measures stress hormone levels after heart attacks. The test – costing just £10 – could ensure patients receive timely life-saving treatment.

COVID-19 increased public trust in science, new survey shows

A survey of over 2000 British adults has found that public trust in science, particularly genetics, increased significantly during the pandemic. However, those with extremely negative attitudes towards science tend to have high self-belief in their own understanding despite low textbook knowledge.

Gero Miesenböck awarded 2023 Japan Prize

Congratulations to Professor Gero Miesenböck, Department of Physiology, Anatomy and Genetics (DPAG), who has been awarded the 2023 Japan Prize in the field of Life Sciences, together with Professor Karl Deisseroth, for pioneering work in the field of optogenetics.